Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

home / authors / rakesh-popat-bsc-mbbs-mrcp-frcpath-phd

Articles

Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 25th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Dr. Popat on Mitigating Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

October 8th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Dr. Popat on Weighing Belantamab Mafodotin–Related Toxicities in Multiple Myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

September 27th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Popat on Unmet Needs in Triple-Class Refractory Multiple Myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

November 5th 2020

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

$Dr. Popat on the DREAMM-1 Trial in Relapsed/Refractory Multiple Myeloma$

Dr. Popat on the DREAMM-1 Trial in Relapsed/Refractory Multiple Myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

November 28th 2019

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.